Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$11.01 USD
-1.17 (-9.61%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.99 -0.02 (-0.18%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Cabaletta Bio, Inc. [CABA]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Keeping Up with Cabaletta''s Progress; Raise PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
We''re Not Ready to Pump the Brakes on CABA-201; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CABA 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Target Up to $25 as We Try to Keep Up with Cabaletta
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
All Gas, No Brakes: CABA-201 Clears IND for Study in gMG
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Systemic Sclerosis a Natural Next Indication for CABA-201; Still Just Scratching the Surface
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Opportunity Keeps Getting Bigger and Bigger; PT Up to $17; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Race is On and Cabaletta Takes the Lead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
CABA-201 Gets Cabalettas Undivided Attention; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Cabaletta Bios CEO; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
CABA-201 Poised to be First CAR-T in Pivotal Studies for Autoimmune Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Cabalettas CARTA Platform to Enter the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
CABA-201 Standing Front and Center; Raise PT to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Don''t Overlook Lancet Report on Anti-CD19 CAR T Cell Therapy for Myositis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Addition of CD19-targeting CAR-T Broadens Cabaletta''s Pipeline in Autoimmune Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cabaletta Bio, Inc.
Industry: Medical - Biomedical and Genetics
Pulling Levers to Win; Management Implements Dosing Changes to Accelerate Clinical Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D